Sideline Gold on Fe...
Health Care: Drugs
Cadence Pharmaceuticals Inc. (CADX: NASDAQ)
$6.89 -0.04 | -0.58%
06/18/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 50.18M | 16.70M | 0.00 | 0.00 |
| Cost of Sales | 21.59M | 10.33M | 0.00 | 0.00 |
| Gross Operating Profit | 28.59M | 6.37M | 0.00 | 0.00 |
| Selling, General, and Administrative Expenses | 86.84M | 81.50M | 39.35M | 24.62M |
| Research & Development | 6.52M | 8.88M | 13.76M | 19.46M |
| Operating Income before D & A (EBITDA) | -64.77M | -84.02M | -53.10M | -44.08M |
| Depreciation & Amortization | 3.01M | 3.65M | 1.13M | 756.21K |
| Interest Income | 123.00K | 136.00K | 106.00K | 181.71K |
| Other Income - Net | -1.15M | -1.07M | -1.50M | -450.96K |
| Special Income / Charges | -7.72M | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -76.52M | -88.60M | -55.63M | -45.11M |
| Interest Expense | 4.45M | 4.42M | 2.14M | 1.14M |
| Pre-Tax Income | -80.97M | -93.02M | -57.77M | -46.25M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -80.97M | -93.02M | -56.64M | -45.49M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -80.97M | -93.02M | -56.64M | -45.49M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -80.97M | -93.02M | -56.64M | -45.49M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-73.25M | -93.02M | -56.64M | -45.49M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -80.97M | -93.02M | -56.64M | -45.49M |
| Basic EPS from Continuing Ops. | -0.95 | -1.41 | -1.09 | -0.93 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.95 | -1.41 | -1.09 | -0.93 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.95 | -1.41 | -1.09 | -0.93 |
| Basic Normalized Net Income/Share | -0.86 | -1.41 | -1.09 | -0.93 |
| EPS fr Continuing Ops. | -0.95 | -1.41 | -1.09 | -0.93 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.95 | -1.41 | -1.09 | -0.93 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.95 | -1.41 | -1.09 | -0.93 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.86 | -1.41 | -1.09 | -0.93 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with CADX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Setting Up...
- ContributorBreakout Stocks Of The Week...
- User8 Stocks Under $10 Making B...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- Contributor8 Stocks Below $10 To Avoid
Latest CADX Headlines from TheStreet
- 8 Stocks Under $10 Trending Sharply Higher 05.14.13 | 11:05 pm
- 4 Health Care Stocks Under $10 to Watch 04.16.13 | 03:04 pm
- 5 Stocks Poised for Breakouts 04.05.13 | 02:04 pm
- 5 Stocks Under $10 Triggering Breakouts 03.21.13 | 01:03 pm
- Stocks Under $5: Discount Drug Name
11.29.12 | 06:11 am - 8 Stocks Under $10 Making Big Moves 08.23.12 | 02:08 pm
- Cadence Pharmaceuticals' Management Presents At The 2012 Wedbush PACGROW Life Sciences Management Access Conference (Transcript) 08.14.12 | 09:08 pm
- Cadence Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript 08.03.12 | 01:08 am
- 7 Stocks Under $10 With Relative Strength 07.06.12 | 02:07 pm
- 8 Stocks Under $10 to Avoid at All Costs 12.23.11 | 12:12 pm
Press Releases for CADX
- Cadence Pharmaceuticals Announces Proposed Public Offering Of Common Stock - PR Newswire 11.08.10 | 06:11 am
Partner Headlines for CADX
- Cadence: Not Altering Sales Projections Or Rating In Aftermath Of Product Recall - Seeking Alpha 02.08.12 | 09:02 am
- Cadence Pharmaceuticals: Good For Patients, Bad For Investors - Seeking Alpha 12.26.11 | 08:12 am
- Wedbush Lowers Cadence PT to $10 from $15 - Benzinga 11.23.11 | 01:11 pm
- Company News for November 18, 2011 - Corporate Summary - Zacks 11.18.11 | 10:11 am
- Options Brief: Cadence Pharmaceuticals - Benzinga 07.15.11 | 01:07 pm
- Cadence: Not Unduly Concerned About ANDA Filing Against Ofirmev - Seeking Alpha 07.05.11 | 09:07 am
- 6 Speculative Biotech Stocks Smart Money Loves - Seeking Alpha 05.23.11 | 09:05 am
- Top 15 Most Undervalued Biotech Stocks By Analyst Target Price - Seeking Alpha 04.08.11 | 03:04 pm
- Future Biotech Superstars - Seeking Alpha 03.30.11 | 09:03 am
- Cadence Pharmaceuticals: A Rising Star - Seeking Alpha 03.13.11 | 09:03 am
